Following positive clinical data , retatrutide, a novel peptide therapy for managing non-insulin dependent diabetes , has obtained regulatory approval from Great Britain's Healthcare and Products Agency ( https://sachinzqsg941383.webbuzzfeed.com/41570586/retatrutide-compound-peptide-british-authorization-and-availability